



Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 4, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan. 4, 2023--

[Kezar Life Sciences, Inc.](#) (Nasdaq: [KZR](#)), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that John Fowler, Co-founder and Chief Executive Officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 2:15 pm PT in San Francisco, CA.

A webcast from the presentation will be available on the "Events & Presentations" section of the Company's website at www.kezarlifesciences.com. Following the event, an archived webcast will be available on the Kezar website for 90 days.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing novel treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor has completed a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company's platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20230104005131/en/>

Investor:

Gitanjali Jain
Vice President, Investor Relations and External Affairs
gjain@kezarbio.com

Media:

Julia Deutsch
Solebury Strategic Communications
jdeutsch@soleburystat.com

Source: Kezar Life Sciences, Inc.